BOSTON, March 11, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced that it will host a conference call and webcast at 10 a.m. Eastern Time on Tuesday, March 24, 2015 to discuss fourth quarter and fiscal year 2014 financial results, and to discuss the Company's progress. The call will be led by Amit Munshi, President and Chief Executive Officer, and Tom Shea, Chief Financial Officer.
Links to a live audio webcast and replay of the presentation may be accessed on the EPIRUS website at http://ir.epirusbiopharma.com/index.cfm. To access the conference call, please dial 1-855-638-3957 (United States) or 1-224-633-1318 (International). The conference ID is 2890190. Please connect to either the conference call or webcast at least 10 minutes early to ensure adequate time to register.
About EPIRUS Biopharmaceuticals
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a global biosimilar company focused on improving patient access to important medicines. EPIRUS' operationally synergistic pipeline of biosimilar product candidates includes BOW015 (infliximab), BOW050 (adalimumab) and BOW070 (tocilizumab). The reference products for these candidates – Remicade, Humira® and Actemra®, respectively – together generated over $20 billion in global sales for 2013, according to EvaluatePharma®. EPIRUS has developed distinct strategies to access its targeted markets with the goal to build a profitable and sustainable biosimilar business. For more information visit our website at www.epirusbiopharma.com.
Remicade is a registered trademark of Johnson and Johnson (www.jnj.com)
Humira is a registered trademark of AbbVie (www.abbvie.com)
Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group (www.gene.com)
Infimab is a registered trademark of Ranbaxy Laboratories (www.ranbaxy.com)
CONTACT: EPIRUS Biopharmaceuticals, Inc. Jennifer Almond, +1-617-606-3288 firstname.lastname@example.org